Teva Pharmaceutical Industries Ltd

Robyn Ryan
August 5, 2017

The company now has an average rating of Hold and an average price target of $42.89.

Teva will also cease operations in 45 countries before the end of 2017. Relative volume is ratio between current volume and 3-month average value, intraday adjusted. Credit Suisse Group lowered shares of Teva Pharmaceutical Industries Limited from an "outperform" rating to a "neutral" rating in a report on Friday. Vetr raised shares of Teva Pharmaceutical Industries Limited from a "hold" rating to a "buy" rating and set a $33.12 price target on the stock in a research note on Tuesday, May 2nd. The company has analyst rating of 2.50 on scale of 1-5.

Shares of Teva Pharmaceutical Industries Limited (TEVA) opened at 23.75 on Friday. The stock's average target of $67.40 is 40.30% above today's ($48.04) share price. The firm has a 50-day moving average of $32.05 and a 200 day moving average of $32.28. The stock volatility for week was 2.14% while for month was 2.56%.The stock, as of recent trade, traded -12.56% to its 52 week low and was changed -56.75% from its 52 week high.

In June, Teva nominated four new directors in an effort to address investor concerns that its board lacked global pharmaceutical experience. Stock traders purchased 66,716 put options on the stock. Company fiscal year is ending in December and analysts' consensus recommendation is Hold for TEVA and estimated EPS for next quarter is $ 1.20. To make a proper assessment, investors seek a sound estimate of this year's and next year's earnings per share (EPS), as well as a strong sense of how much the company will earn even farther down the road. Now the P/E of Teva Pharmaceutical Industries Limited (TEVA) stands at 224.06.

Specialty revenue dropped 9% during the quarter. During the same period in the prior year, the business posted $1.25 EPS.

While looking at the Stock's Performance, Teva Pharmaceutical Industries Limited now shows a Weekly Performance of -5.42%, where Monthly Performance is -6.18%, Quarterly performance is 1.73%, 6 Months performance is -9.92% and yearly performance percentage is -40.99%.

TRADEMARK VIOLATION WARNING: "Teva Pharmaceutical Industries Limited (TEVA) PT Set at $27.00 by Cantor Fitzgerald" was reported by Markets Daily and is the property of of Markets Daily.

At last check, shares of Teva Pharmaceutical are down by 8.2%, to $21.78 a share, in early trading Friday. Northstar Group Inc. now owns 24,048 shares of the company's stock valued at $799,000 after buying an additional 2,500 shares during the last quarter. Teva Pharmaceutical Inds Ltd now has $24.27 billion valuation. The stock had a trading volume of 62,024,408 shares.

Israeli company Teva Pharmaceutical Industries has announced that it will be firing 7,000 of its employees worldwide, including in Israel, due to reported $6 billion loss. Schulhoff & Co. Inc. now owns 11,601 shares of the company's stock valued at $372,000 after buying an additional 1,004 shares during the last quarter. Finally, Berson & Corrado Investment Advisors LLC bought a new stake in Teva Pharmaceutical Industries during the first quarter worth $1,072,000. Zacks Investment Research's sales averages are an average based on a survey of sell-side analysts that follow Teva Pharmaceutical Industries. HNGR's SI was 1.13 million shares in August as released by FINRA.

In total: Teva's primary businesses are performing poorly, the company is still searching for a new CEO, it carries a mountain of debt, and its largest shareholder now has the green light to look for an exit. The Firm is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Other reports by VideoGamingPros

Discuss This Article